

Urteste S.A.  
1 Starodworska Street  
80-137 Gdansk

20.03.2025

**Current report number 3/2025  
dated 20.03.2025**

Subject: Obtaining patent protection from the Patent Office of the Republic of Poland for invention in the MULTI-CANCER project

Legal basis: Article 17(1) MAR - confidential information.

The Management Board of Urteste S.A. headquartered in Gdansk, Poland ("Issuer", "Company") informs that today, i.e. March 20, 2025, the Company has received information that the Patent Office of the Republic of Poland has granted a patent for the invention in the MULTI-CANCER project entitled. "Compound - a diagnostic marker for biliary tract cancer, a method of detecting enzymatic activity, a method of diagnosing biliary tract cancer, a kit containing such a compound and applications of such a compound".

The patent was granted for a period of 20 years from the filing date, i.e. January 9, 2023, subject to payment of fees for the first period of protection, which will be paid immediately by the Issuer.

The Company's Management Board considered the above information confidential due the fact that MULTI-CANCER is, besides the Issuer's main project, PANURI, the second key project being implemented by the Company, and obtaining patent protection increases the likelihood of implementing this project, which, in the opinion of the Issuer's Management Board, may have a positive impact on the Company's development and future situation.